COVID‐19: Herd immunity and convalescent plasma transfer therapy

Syal, Kirtimaan

doi:10.1002/jmv.25870

Cited by 84 publications

(103 citation statements)

References 18 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Previous reviews have stated that the CPT may be considered for critically sick COVID-19 patients based on the earlier reported studies. 17,18 In this systematic review of CPT to the COVID-19 patients, we identified and critically evaluated five studies that described about 27 patients. All studies reported good outcomes after CPT performance, but all were considered to have risk of bias owing to a combination of non-randomized evaluations, confounding, predictor description and poor methodological conduct for participant selection, dosage of CPT, and duration of therapy.…”

Section: Discussionmentioning

confidence: 99%

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Rajendran

Narayanasamy

Rangarajan

et al. 2020

Journal of Medical Virology

313

308

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Rajendran

Narayanasamy

Rangarajan

et al. 2020

Journal of Medical Virology

313

308

View full text Add to dashboard Cite

show abstract

“…Above the herd immunity threshold (HIT) the infection may no longer persist in the population. The HIT of SARS-CoV-2 is estimated at 50 to 67%, but the incidence of symptomatic and asymptomatic SARS-CoV-2 cases in an epidemic setting is unclear to date 10 .…”

Section: Introductionmentioning

confidence: 99%

Herd immunity is not a realistic exit strategy during a COVID-19 outbreak

Slot

Hogema

Reusken

et al. 2020

Preprint

View full text Add to dashboard Cite

The world is combating an ongoing COVID-19 pandemic1-4. Health-care systems, society and the economy are impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak5-9. Natural herd immunity has been suggested as a potential exit strategy during COVID-19 outbreaks, which may arise when 50-67% of a community has been infected10. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of a highly affected country using a novel immunoassay, indicating that one month into the outbreak (i) the seroprevalence in the Netherlands is 2.7% with substantial regional variation, (ii) the hardest-hit areas show a seroprevalence of up to 9.5%, (iii) the seroprevalence is sex-independent throughout age groups (18-72 years), (iv) antibodies are significantly more often detected in younger people (18-30 years), and (v) the number of immune individuals in the current epidemic stage is far below the herd immunity threshold. This study provides vital information on the extent of virus spread in a country where social distancing is in place, concluding that herd immunity to SARS-CoV-2 is not a realistic short-term exit strategy option.

show abstract

“…Using an estimated R 0 of 3, the estimated proportion of the world's population that needs to develop immunity to SAR-CoV2 to develop herd immunity is approximately 70%. 39 Considering the risk of severe disease in a significant number, herd immunity would preferably be best obtained through vaccination. The WHO is coordinating with a group of experts for vaccine development.…”

Section: Immunitymentioning

confidence: 99%

Epidemiology of COVID-19

Chowdhury

Oommen

2020

Journal of Digestive Endoscopy

113

View full text Add to dashboard Cite

COVID-19, an infectious respiratory illness caused by the severe acute respiratory syndrome–corona virus 2 (SARS-CoV2), has now spread to multiple countries including India. The pace at which the disease spread in the last 4 months, since it was first recognized from China, is unprecedented. This review of the epidemiology of COVID-19 summarizes the burden of infection, transmission dynamics, and other related epidemiological features. While countries such as China, Italy, and the United States have particularly high-rates of infection, the disease is gradually spreading in India as well, threatening the health and economy of the country. Transmission in asymptomatic cases, early symptomatic phase, as well as limited access to testing in different settings are factors that have led to the rapid spread of infection. A large case series from China revealed that 81% of cases had mild symptoms, 14% had severe disease, and 5% were afflicted with critical illness. While the mortality in China was reported as 2.3%, Italy, with a high-proportion of elderly, reported a case fatality report of 7.2% due to higher infection and mortality rates among the elderly. Being a highly infectious disease, with a basic reproduction number between 2 to 3, COVID-19 is affecting a large number of healthcare workers, as evidenced by the fact that a sizeable portion of reported infections in the US included healthcare workers. Delivering health care for both COVID-19 affected individuals, as well those with other acute and chronic conditions, with limited access to healthcare facilities and services, are challenges for the health systems in low- and middle-income countries, which require immediate measures for health system strengthening across sectors.

show abstract

COVID‐19: Herd immunity and convalescent plasma transfer therapy

Cited by 84 publications

References 18 publications

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Herd immunity is not a realistic exit strategy during a COVID-19 outbreak

Epidemiology of COVID-19

Contact Info

Product

Resources

About